Pancreatic Myeloid Sarcoma

Curēus
Ammar Al-ObaidiSeth Page

Abstract

Myeloid sarcoma is an isolated extramedullary tumor mass consisting of immature myeloid cells. It is characterized by highly variable outcomes and usually disrupts the normal architecture of the normal tissue in which it originates. It may occur de novo or be associated with other hematological malignancies. Clinical presentation of myeloid sarcomas can be highly variable based on the tumor site, size, and extent of tissue involvement. The diagnosis of myeloid sarcoma is challenging and requires a high index of suspicion. Tissue sampling followed by the use of auxiliary studies is essential for diagnosis. Moreover, bone marrow sampling is necessary to exclude morrow involvement. Currently, the recommended therapeutic regimens for myeloid sarcoma are similar to those for acute myeloid leukemia. Much work remains to be accomplished as myeloid sarcomas, if initially missed or misdiagnosed, have poor overall survival rates. Furthermore, prognostic factors for this malignancy remain poorly understood.

Methods Mentioned

BETA
MDS
bone
biopsy
light microscopy
surgical resection

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Anais Brasileiros De Dermatologia
Erica Rodrigues de Araujo VasconcelosMayra Carrijo Rochael
Acta Medica Croatica : C̆asopis Hravatske Akademije Medicinskih Znanosti
Biljana Jelić-PuskarićBranimir Jaksić
Revista brasileira de hematologia e hemoterapia
Luzia Beatriz Ribeiro ZagoLeonardo Rodrigues de Oliveira
© 2022 Meta ULC. All rights reserved